VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Friday. The firm set a “sell” rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Price Performance

NYSE:VNRX opened at $0.69 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The stock’s 50 day simple moving average is $0.65 and its two-hundred day simple moving average is $0.69. The company has a market cap of $63.78 million, a price-to-earnings ratio of -1.73 and a beta of 1.09.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. As a group, analysts anticipate that VolitionRx will post -0.31 EPS for the current year.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes bought 150,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $0.67 per share, for a total transaction of $100,500.00. Following the acquisition, the director now owns 406,683 shares in the company, valued at $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.